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OBJECTIVES The purpose of this study was to investigate the effects of a selective alpha2-adrenergic
agonist, alpha-methylnorepinephrine (alphaMNE) as an alternative vasopressor agent during
cardiopulmonary resuscitation (CPR).
BACKGROUND For more than 40 years, epinephrine has been the vasopressor agent of choice for CPR. Its
beta- and alpha1-adrenergic effects increase myocardial oxygen consumption, magnify global
myocardial ischemia and increase the severity of postresuscitation myocardial dysfunction.
METHODS Ventricular fibrillation (VF) was induced in 20 Sprague-Dawley rats. After 8 min of untreated
VF, mechanical ventilation and precordial compression began. AlphaMNE, epinephrine or
saline placebo was injected into the right atrium 2 min after the start of precordial
compression. As an additional control, one group of animals was pretreated with alpha2-
receptor blocker, yohimbine, before injection of alphaMNE. Defibrillation was attempted
4 min later. Left ventricular pressure, dP/dt40, negative dP/dt and cardiac index were
measured for an interval of 240 min after resuscitation.
RESULTS Except for saline placebo and yohimbine-treated animals, comparable increases in coronary
perfusion pressure were observed after each drug intervention. All animals were successfully
resuscitated. Left ventricular diastolic pressure, cardiac index, dP/dt40 and negative dP/dt
were more optimal after alphaMNE; this was associated with significantly better postresus-
citation survival. Pretreatment with yohimbine abolished the beneficial effects of alphaMNE.
CONCLUSIONS The selective alpha2-adrenergic agonist, alphaMNE, was as effective as epinephrine for initial
cardiac resuscitation but provided strikingly better postresuscitation myocardial function and
survival. (J Am Coll Cardiol 2001;37:951–6) © 2001 by the American College of Cardiology
Rapid restoration of threshold levels of coronary perfusion
and, therefore, myocardial blood flow during cardiopulmo-
nary resuscitation (CPR) has been the overriding determi-
nant of successful restoration of spontaneous circulation.
Adrenergic vasopressor agents are employed to increase
peripheral vascular resistance such as to increase aortic
diastolic pressure and, consequently, coronary perfusion
pressure and myocardial blood flow (1,2). The success of
electrical defibrillation is contingent on restoring threshold
levels of myocardial blood flow, especially when the dura-
tion of cardiac arrest is prolonged (3). Epinephrine, which
has both alpha- and beta-adrenergic effects, enhances cor-
onary perfusion during CPR. However, the beta- and, to a
lesser extent, the alpha1-adrenergic inotropic and chrono-
tropic actions increase oxygen consumption of the fibrillat-
ing ventricles. Consistent with the historically important
report by Redding et al. (4), current evidence suggests that
these increases in oxygen demand before and during resus-
citation are not compensated for by concurrent increases in
myocardial blood flow (5). Accordingly, epinephrine in-
creases the severity of myocardial ischemia during CPR.
Increases in unmet oxygen demands are likely to account for
greater postresuscitation myocardial dysfunction and de-
creased postresuscitation survival after restoration of spon-
taneous circulation (2,6). We hypothesized that a selective
alpha2-adrenergic agonist would likely be a better vasopres-
sor agent in settings of CPR. Activation of both beta- and
alpha1-adrenergic receptors in the myocardium account for
both inotropic and chronotropic actions (7). This contrasts
with alpha2-agonists for which no receptors have been
identified in the myocardium (8). In this study, the effects of
a selective alpha2-adrenergic agonist administered during
CPR were compared with epinephrine with respect to initial
resuscitation, postresuscitation myocardial function and
postresuscitation survival after prolonged cardiac arrest. We
also sought to validate our hypothesis by blocking the effects
of the selective alpha2-agonist with yohimbine.
METHODS
The protocol was approved by the Institutional Animal
Care and Use Committee. All animals received humane care
in compliance with the principles of laboratory animal care
formulated by the National Society for Medical Research
and the Guide for the Care and Use of Laboratory Animals
prepared by the Institute of Laboratory Animal Resources
From the *Institute of Critical Care Medicine, Palm Springs, California, and †Keck
School of Medicine of the University of Southern California, Los Angeles, California.
Supported, in part, by a grant HL54322 from the National Heart, Lung and Blood
Institute, Bethesda, Maryland; the Established Investigator Research Grant (Dr.
Tang) from the Society of Critical Care Medicine, Anaheim, California; and a
Grant-in-Aid from Abbott Laboratories, Hospital Products Division, Morgan Hill,
California.
Manuscript received July 17, 2000; revised manuscript received October 16, 2000,
accepted November 17, 2000.
Journal of the American College of Cardiology Vol. 37, No. 3, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(00)01188-8
and published by the National Institutes of Health (NIH
publication 86-32, revised 1996).
Animal preparation. Twenty male Sprague-Dawley rats
weighing 450 to 550 g were fasted overnight except for free
access to water. The animals were anesthetized by an
intraperitoneal injection of 45 mg/kg pentobarbital sodium.
Additional doses of 10 mg/kg were administered at hourly
intervals but not within 30 min preceding onset of cardiac
arrest. The trachea was orally intubated with a 14 g cannula
mounted on a blunt needle (Abbocath-T, Abbott Hospital
Inc., North Chicago, Illinois) with a 145° angled tip as
previously described (2,6,9). End tidal blood carbon dioxide
tension (PETCO2) was measured with a side-stream infra-
red CO2 analyzer (model 200, Instrumentation Laborato-
ries, Lexington, Massachusetts) interposed between the
tracheal cannula and the respirator. For measurement of left
ventricular pressure, measured at an intraventricular pres-
sure of 40 mm Hg (dP/dt40) and negative dP/dt, a 23-gauge
polyethylene catheter (Intramedic PE 50, Becton Dickin-
son, Sparks, Maryland) was advanced from the right carotid
artery into the left ventricle. A 23-gauge polyethylene
catheter (PE 50, Becton Dickinson, Sparks, Maryland) was
advanced through the left external jugular vein, through the
superior vena cava and into the right atrium. Intracardiac
pressures were measured with reference to the midchest
with a high sensitivity pressure transducer (model 42584-
01, Abbott Critical Care System, North Chicago, Illinois).
A 4F polyethylene catheter (model C-PMS-401J, Cook
Critical Care, Bloomington, Indiana) was advanced through
the right external jugular vein into the right atrium. A
precurved guidewire supplied with the catheter was then
advanced through the catheter into the right ventricle until
an endocardial electrogram was confirmed. A 23-gauge
polyethylene catheter (PE 50, Becton Dickinson, Sparks,
Maryland) was advanced through the left femoral artery into
the thoracic aorta for measurement of aortic pressure with a
high sensitivity pressure transducer (model 42584-01, Ab-
bott Critical Care System, North Chicago, Illinois). A
thermocouple microprobe, 10 cm in length and 0.5 mm in
diameter (9030-12-D-34, Columbus Instruments, Colum-
bus, Ohio), was advanced from the right femoral artery into
the descending thoracic aorta. Blood temperature was mea-
sured with this sensor. A 23-gauge polyethylene catheter
(PE 50, Becton Dickinson, Sparks, Maryland) was ad-
vanced through the right femoral vein into the inferior vena
cava for sampling venous blood and for blood transfusion.
The electrocardiogram lead II was continuously recorded.
Experimental procedure. The experimental protocol is
summarized in Figure 1. Fifteen minutes before inducing
ventricular fibrillation (VF), the animals were randomized
by the sealed envelope method as previously described (6).
The investigators were blinded to each intervention. For
animals randomized to receive the selective alpha2-
adrenergic receptor blocking agent, yohimbine, a dose of
100 mg/kg was injected into the right atrium 15 min before
inducing VF. Ventricular fibrillation was induced with a 60
cycle alternating current of 3 mA delivered to the right
ventricular endocardium. The current flow was continued
for 3 min to sustain VF (2,6,9). Mechanical ventilation was
discontinued after onset of VF. Precordial compression was
begun 8 min after onset of VF with a pneumatically driven
mechanical chest compressor as previously described (2,6,9).
Coincident with the start of precordial compression, the
animal was mechanically ventilated. Tidal volume was
established at 0.65 ml/100 g animal weight, a frequency of
100/min and with an inspired oxygen fraction (FiO2) of 1.0.
Precordial compression at a rate of 200 min21 was synchro-
nized to provide a compression/ventilation ratio of 2:1 with
an equal compression-relaxation duration. Depth of com-
pression was adjusted to maintain the coronary perfusion
pressure at 23 6 2 mm Hg. This typically yielded a
PETCO2 of 11 6 2 mm Hg. Either 100 mg/kg of alpha-
methylnorepinephrine (alphaMNE), 30 mg/kg of epineph-
rine or saline placebo was injected into the right atrium over
a 10 s interval beginning 2 min after the start of precordial
compressions. Resuscitation was attempted with up to
three, 2 J countershocks after 14 min of cardiac arrest and
6 min after the start of precordial compression. Restoration
of spontaneous circulation was defined as the return of
supraventricular rhythm with a mean aortic pressure of
60 mm Hg for a minimum of 5 min. Mechanical ventilation
with an FiO2 1.0 was continued for 4 h after successful
resuscitation. All catheters, including the endotracheal tube,
were then removed. The animals were observed for an
additional 68 h after which they were euthanized with an
intraperitoneal injection of pentobarbital. At autopsy, or-
gans were inspected for gross abnormalities, including
Abbreviations and Acronyms
alphaMNE 5 alpha-methylnorepinephrine
CPR 5 cardiopulmonary resuscitation
dP/dt40 5 measured at an intraventricular pressure of
40 mm Hg
FiO2 5 inspired oxygen fraction
PCO2 5 blood carbon dioxide tension
PETCO2 5 end tidal PCO2
VF 5 ventricular fibrillation Figure 1. Experimental procedures. DF 5 defibrillation; Drug 5 either
alphaMNE, epinephrine or saline placebo; FiO2 5 inspired oxygen
fraction; MV 5 mechanical ventilation; PC 5 precordial compression;
VF 5 ventricular fibrillation. *For alpha2-receptor block (only in the group
of animals which received alpha-methylnorepinephrine during cardiopul-
monary resuscitation).
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evidence of traumatic injury consequent to cannulation,
airway management or precordial compression.
Measurements. Aortic, left ventricular and right atrial
pressures, electrocardiogram and PETCO2 were continu-
ously recorded on a PC-based data acquisition system
supported by CODAS software (DATAQ Inc, Akron,
Ohio). Coronary perfusion pressure was calculated as the
difference between decompression diastolic aortic and time-
coincident right atrial pressure measured at the end of each
minute of precordial compression. A 1.0-ml aliquot of
arterial blood from a donor rat of the same colony was
transfused into the inferior vena cava immediately after
withdrawal of 0.5-ml samples from the aortic and from the
inferior vena cava catheter. Blood oxygen tension, blood
carbon dioxide tension (PCO2) and lactic acid were mea-
sured on these samples by techniques previously described
(2,6,9). At 5 min after the start of precordial compression
and at 120 and 240 min after successful resuscitation, this
panel of measurements was repeated. Myocardial function
was assessed from measurements of left ventricular pressures
and cardiac output. The rate of left ventricular pressure
increase was measured by analog differentiation of left
ventricular pressure at 40 mm Hg (dP/dt40) for quantitation
of isovolemic contractility. The rate of maximal left ventric-
ular pressure decline (2dP/dt) was measured as an estimate
of myocardial relaxation (2,6,9). Cardiac output was mea-
sured by a thermodilution technique in which a bolus of
200 ml of saline at a temperature of 12°C was injected into
the right atrium. Duplicate thermodilution curves were
obtained with the aid of a cardiac output computer fabri-
cated by our institute. Duplicate measurements in each
instance differed by 5%.
Statistical analyses. For measurements between groups,
analysis of variance and Scheffe’s multicomparison tech-
niques were used. Comparisons between time-based mea-
surements within each group were performed with analysis
of variance repeated measurements. The outcome differ-
ences were analyzed with Fisher exact test. Measurements
are reported as mean 6 standard deviation. A value of p ,
0.05 was considered significant.
RESULTS
Baseline hemodynamic and blood analytical measurements
did not differ significantly among the four groups. There
were no differences in aortic pressure and blood gas mea-
surements between groups during CPR and after successful
resuscitation. After administration of alphaMNE, coronary
perfusion pressure was increased from 24 6 1 to 30 6
2 mm Hg (p , 0.01). Comparable increases in coronary
perfusion pressure from 23 6 1 to 30 6 3 mm Hg (p ,
0.01) were observed with epinephrine. In animals pretreated
with yohimbine, no increases in coronary perfusion pressure
followed administration of alphaMNE (Fig. 2). Though
comparable increases in coronary perfusion pressure were
observed after both alphaMNE and epinephrine, PETCO2
was unaffected by alphaMNE, but it was significantly
decreased after epinephrine (Fig. 2). All animals were
successfully resuscitated after electrical defibrillation. The
number of electrical shocks required for restoration of
spontaneous circulation was significantly greater in placebo-
treated animals (p , 0.01) and epinephrine-treated animals
(p , 0.05) compared to animals treated with alphaMNE.
The total number of postresuscitation ventricular ectopic
beats during the first 10 min after successful resuscitation
was significantly greater in both placebo-treated and
epinephrine-treated animals (Table 1). As we previously
observed, dP/dt40 was significantly decreased in all animals
after successful resuscitation (2,6). Decreased contractility
was associated with a significant decrease in cardiac index
(Fig. 3 and 4). However, alphaMNE significantly reduced
the severity of myocardial contractile dysfunction. This
contrasted with animals treated with epinephrine or with
saline placebo in which there was greater impairment of
myocardial contractility. After alphaMNE, we also observed
Figure 2. Effects of four interventions on CPP and ETCO2 during
precordial compression. Values are mean 6 standard deviation. aMNE 5
alpha-methylnorepinephrine; aMNE1Y 5 alpha-methylnorepinephrine
pretreated with yohimbine; CPP 5 coronary perfusion pressure; drug 5
the time of administration of the drugs; Epi. 5 epinephrine; ETCO2 5
end tidal PCO2; PC 5 precordial compression. *p , 0.05; **p , 0.01.
Table 1. Effects of Treatment on Number of Defibrillation, Postresuscitation Ventricular
Arrhythmias and Duration of Survival
Treatment
Number of
Defibrillations PVCs Survival (h)
Alpha-methylnorepinephrine 1.6 6 0.9†\ 287 6 342*§ 72 6 0†\
Alpha-methylnorepinephrine with yohimbine 3.0 6 0.7‡§ 687 6 642 20 6 7
Epinephrine 3.8 6 1.9 1,097 6 816 19 6 8
Control 4.9 6 0.8 1,054 6 605 16 6 4
*p , 0.05; †p , 0.01 vs. epinephrine; ‡p , 0.05 vs. alpha-methylnorepinephrine; §p , 0.05; \p , 0.01 vs. control.
PVCs 5 ventricular ectopic beats during the first 10 min after resuscitation.
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improvement in 2dP/dt and, therefore, myocardial relax-
ation (Fig. 5) together with left ventricular end diastolic
pressure (Fig. 6). These myocardial protective effects of
alphaMNE were fully blocked by pretreatment with yohim-
bine. Finally, the duration of postresuscitation survival was
also significantly improved after alphaMNE. Each animal
treated with alphaMNE survived for more than 72 h. This
contrasted with epinephrine-treated animals, which sur-
vived for an average of 19 h, and placebo controls, which
survived for an average of 16 h (Table 1). These beneficial
effects of alphaMNE on postresuscitation survival were also
blocked by yohimbine.
DISCUSSION
Like epinephrine, alphaMNE increases coronary perfusion
pressure to levels that favor successful resuscitation in our
animal model. However, electrical defibrillation was
achieved with greater ease and with significantly less total
electrical energies after treatment with alphaMNE. End
tidal PCO2 remained unchanged after alphaMNE, which
indicated that, unlike epinephrine, this selective alpha2-
adrenergic agent does not produce pulmonary ventilation/
perfusion defects (10). After successful resuscitation, the
incidence of postresuscitation ventricular arrhythmias was
strikingly reduced after administration of alphaMNE, and
there was a highly significant reduction in postresuscitation
myocardial dysfunction in animals treated with alphaMNE.
These beneficial effects were associated with a significantly
increased duration of postresuscitation survival. Pretreat-
ment with yohimbine abolished these beneficial effects,
confirming our hypothesis that selective alpha2-adrenergic
receptor activation provided a better option than epineph-
rine. There is a slight likelihood of successful cardiac
resuscitation without reestablishment of threshold levels of
coronary perfusion, especially if the duration of cardiac
arrest is prolonged. Since coronary and cerebral circulation
is directly related to the arterial pressures generated, vaso-
constrictor agents serve to increase peripheral vascular re-
sistance and, thereby, preferentially increase coronary and
cerebral blood flows. This is the rationale for the routine use
of vasopressor agents during CPR (11).
Potential limitations of epinephrine during CPR. Epi-
nephrine has been the preferred adrenergic amine for the
treatment of human cardiac arrest for almost 40 years
(1,12–14). However, epinephrine has potent effects on both
Figure 3. Effects of four interventions on postresuscitation dP/dt40. Values
are mean 6 standard deviation. aMNE 5 alpha-methylnorepinephrine;
aMNE1Y 5 alpha-methylnorepinephrine pretreated with yohimbine;
BL 5 baseline; DF 5 defibrillation; Epi. 5 epinephrine; PC 5 precordial
compression; VF 5 ventricular fibrillation. *p , 0.05 vs. epinephrine.
Figure 4. Effects of four interventions on postresuscitation cardiac
index. Values are mean 6 standard deviation. aMNE 5 alpha-
methylnorepinephrine; aMNE1Y 5 alpha-methylnorepinephrine pre-
treated with yohimbine; BL 5 baseline; DF 5 defibrillation; Epi. 5
epinephrine; PC 5 precordial compression; VF 5 ventricular fibrillation.
*p , 0.05; **p , 0.01 vs. epinephrine.
Figure 5. Effects of four interventions on postresuscitation 2dP/dt. Values
are mean 6 standard deviation. aMNE 5 alpha-methylnorepinephrine;
aMNE1Y 5 alpha-methylnorepinephrine pretreated with yohimbine;
BL 5 baseline; DF 5 defibrillation; Epi. 5 epinephrine; PC 5 precordial
compression; VF 5 ventricular fibrillation. *p , 0.05; **p , 0.01 vs.
epinephrine.
Figure 6. Effects of four interventions on postresuscitation LVDP. Values
are mean 6 standard deviation. aMNE 5 alpha-methylnorepinephrine;
aMNE1Y 5 alpha-methylnorepinephrine pretreated with yohimbine;
BL 5 baseline; DF 5 defibrillation; Epi. 5 epinephrine; LVDP 5 left
ventricular end-diastolic pressure; PC 5 precordial compression; VF 5
ventricular fibrillation. *p , 0.05; **p , 0.01 vs. epinephrine.
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alpha- and beta-receptors, including alpha1-, alpha2- and
beta1- and beta2-receptors (Table 2). The beta1- and beta2-
adrenergic actions are inotropic and chronotropic and,
thereby, increase the already excessive myocardial oxygen
requirements of the fibrillating heart. These increases in
oxygen demand fail to be fulfilled by the very limited blood
flow generated by precordial compression, which is only
between 25% to 30% of resting physiological levels (6).
Accordingly, epinephrine produces vasoconstriction and,
thereby, increases coronary perfusion pressure during CPR.
However, postresuscitation myocardial function and survival
decreases as a consequence of the greater severity of global
myocardial ischemia (2).
Potential limitations of selective alpha1-adrenergic ago-
nists during CPR. Activation of alpha-adrenergic recep-
tors account for the increases in peripheral vascular resis-
tance and consequent increases in both myocardial and
cerebral perfusion pressure and blood flow. However, we
now recognize that there is a rapid desensitization of
alpha1-adrenergic receptors when the myocardium becomes
ischemic (15,16). This is consistent with earlier observa-
tions, which indicated that predominant alpha1-agonists,
including methoxamine and phenylephrine, are less effective
than epinephrine after prolonged cardiac arrest (17). In
addition, it is now apparent that stimulation of myocardial
alpha1-adrenergic receptors increases both inotropic and
chronotropic responses, myocardial oxygen consumption
and, thereby, augments global ischemic injury (18). When
alpha1-adrenergic receptors are blocked by either a selective
or nonselective alpha-adrenergic blocker, myocardial func-
tion is significantly improved after acute myocardial infarc-
tion (19). In addition, alpha1-adrenergic agonists constrict
coronary arteries such that there is further reduction in
myocardial blood flow (20).
Rationale for the use of selective alpha2-adrenergic ago-
nists during CPR. Stimulation of postsynaptic alpha2-
adrenergic receptors produces systemic vasoconstriction
without concurrent increases in myocardial oxygen require-
ment (21). Contrasted with alpha1-adrenergic receptors,
stimulation of postsynaptic alpha2-adrenergic receptors in-
creases endothelial nitric oxide production, which counter-
balances alpha2-adrenergic stimulation induced coronary
vasoconstriction (19). Stimulation of presynaptic alpha2-
adrenergic receptors inhibits the release of endogenous
catecholamines. This is likely to be beneficial since greater
levels of endogenous catecholamines during CPR were
associated with poor outcomes (22). These considerations
prompted the concept that selective alpha2-adrenergic ago-
nists may be more optimal vasopressor agents in settings of
cardiac arrest. The rationale for the use of a selective
alpha2-adrenergic agonist is also supported by experimental
studies on regional myocardial ischemia. Clonidine, an
alpha2-adrenergic agonist, decreased the severity of post-
ischemic myocardial dysfunction after 10 min of left ante-
rior descending coronary artery occlusion (23). Perioperative
administration of selective alpha2-adrenergic agonists, in-
cluding clonidine and mivazerol, reduced the severity of
myocardial ischemia in settings of coronary artery disease
(24,25). A major limitation of currently available selective
alpha2-adrenergic agonists, including clonidine, is the ease
with which these drugs cross the blood-brain barrier,
especially when the function of this barrier is decreased
during ischemia (26). In the central nervous system, alpha2-
adrenergic agonists exert a negative inotropic and chrono-
tropic action (27). Accordingly, there is a decline in myo-
cardial contractility and arterial pressure. This prompted the
introduction of alpha2-agonists for the treatment of hyper-
tension, recognizing the risk of initial hypertension due to
its peripheral action. Alpha-methylnorepinephrine, how-
ever, had no such negative inotropic and chronotropic
effects after resuscitation in the present model, consistent
with earlier findings that this agent does not cross the
blood-brain barrier (28,29).
Study limitations. In contrast with settings of human
cardiac arrest, experiments were performed on another
species, namely, mature male rats. The experimental ani-
mals were free of heart disease and anesthetized with
pentobarbital.
CONCLUSIONS
We conclude that the administration of the selective alpha2-
adrenergic agonist, alphaMNE, significantly improves the
outcome of CPR when compared with epinephrine and that
such improvement is associated with lesser postresuscitation
ventricular arrhythmias and better postresuscitation myocar-
dial function.
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